MA13.06 Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2

S.-H. Lee(Samsung Medical Center), M.E. Marmarelis, Shalin Shah(Springhouse), M. Thayu, J.M. Bauml, Alexander I. Spira(Virginia Cancer Specialists), Byoung Chul Cho(Yonsei University), R.E. Knoblauch, Saiama N. Waqar(Washington University in St. Louis), Leonardo Trani(Springhouse), S.-H.I. Ou(Chongqing Medical and Pharmaceutical College), Pauling Chu(Janssen (United States))
Journal of Thoracic Oncology
October 31, 2023
10.1016/j.jtho.2023.09.208
Cited by 4

Related Papers

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835